Press Releases

Atomwise SAB, BOD 2021
Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Experts include Mike Varney, Bruce Roth, John Hamer, Kemal Malik, and Andrew Lo SAN FRANCISCO, Calif., June 17, 2021 – Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on […]


June 17, 2021
BioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic Development

Strategic collaboration to integrate AI technology, drug development expertise and ecosystem of partners for the commercialization of promising early-stage research CLEVELAND & SAN FRANCISCO–(BUSINESS WIRE)–BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, today announced a strategic collaboration to co-develop therapies. The organizations will form co-owned, joint […]

Bayer Exercises Right to Enter Into Follow-On Research and Collaboration Option Agreement With Atomwise

Companies to continue crop protection development programs January 07, 2020 08:30 AM Eastern Standard Time MONHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Bayer and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the companies will continue the development of two crop protection programs. Farmers across the world are facing an increase in weed, insect and […]


January 7, 2020
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery

Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.

Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas

Hansoh Pharmaceutical Group Company Limited, a leading biopharmaceutical company in China, and Atomwise, Inc., the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.


September 11, 2019
Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients

Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.

Atomwise and OncoStatyx announce Joint Venture to develop small molecule inhibitors of oncology target KDM5B

Atomwise and OncoStatyx announce a joint venture to discover and develop small molecule compounds that inhibit KDM5B.


September 10, 2019